← Back to Home

Reactivating Paternal UBE3A: Nonviral CRISPR Delivery Platform Shows Potential in Angelman Syndrome Models

STEP delivers gene-editing tools to the brain, restores gene expression in patient-derived organoids and mice, and distributes widely in nonhuman primate brains. This therapeutic approach has shown functional improvements in animals, but safety requirements preceding human trials have yet to be met.

By SURL BioNews

One possible therapeutic approach for Angelman syndrome is to reactivate the normally silent paternal gene in neurons; the challenge is delivering the tools to enough brain cells. On October 21, the American Society of Human Genetics (ASHG) announced preclinical findings from Yale University researchers: the nonviral delivery platform STEP reactivated UBE3A in patient-derived brain organoids and animal models, while treated mice also showed improvements in behavioral and electroencephalographic measures.

The central problem in Angelman syndrome is a lack of normal UBE3A function in neurons. These cells generally express primarily the maternal copy, while the paternal copy is suppressed by the antisense RNA transcript UBE3A-ATS. The research team is attempting to use CRISPR to disrupt this silencing mechanism, allowing the paternal copy to resume protein production and compensate for the deficient function.

STEP, presented by Xiaona Lu, uses chemical modifications to deliver CRISPR-Cas9 components without viral vectors or lipid nanoparticles. Addgene’s conference recap in August of this year described STEP-RNP as particles approximately 12–14 nanometers in size, carrying ribonucleoprotein complexes composed of Cas9 protein and guide RNA. The design allows the editing tools to remain in cells only briefly; researchers believe this may help limit unintended editing, but safety data are still needed to verify this.

The program has been developing over some time. The Foundation for Angelman Syndrome Therapeutics (FAST), in its recap of the 2025 Science Summit, introduced the same STEP-RNP program as CRG-AS-001 and listed Yale researchers Yong-Hui Jiang and Jiangbing Zhou. The recap reported improvements in motor coordination, cognition, and EEG delta power in disease-model mice treated at different ages; seizure susceptibility also decreased in neonatal and adolescent mice. These findings support further research but do not yet allow predictions that patients will experience the same degree of benefit.

The latest ASHG announcement also brought larger animals into focus: after researchers injected STEP into the cerebrospinal fluid surrounding the brain and spinal cord, imaging showed widespread distribution in nonhuman primate brains, and re-expression of paternal UBE3A was observed. This administration method does not mean that a standard intravenous injection can cross the blood-brain barrier; widespread distribution and restored gene expression also still need to be evaluated separately from long-term functional improvement.

Both ASHG and Addgene reported that the UBE3A activation achieved outperformed benchmarks from published antisense oligonucleotide studies. However, this is a comparison across studies; the currently available public summaries do not provide sufficient information on sample sizes, doses, follow-up periods, or comparative designs for a full assessment, so they cannot establish that STEP is superior to other therapeutic strategies in patients.

The next hurdle is safety. Dose-ranging toxicology studies in nonhuman primates are still underway, and nonviral delivery itself does not guarantee that editing is risk-free. An earlier FAST recap noted that the team was preparing to support a potential future Phase I/II human trial, but whether the program can advance still depends on subsequent safety and efficacy data. For this program, preliminary evidence supports delivery to the brain and gene reactivation; how long the effects can last, and whether they can safely translate into improvements in patients’ lives, are the questions that must be answered next.

References

  1. American Society of Human Genetics
  2. Addgene
  3. Foundation for Angelman Syndrome Therapeutics (FAST)